HeartBeat.bio
Heartbeat.bio is dedicated to transforming cardiac drug discovery through innovative technology. They develop human heart chamber models called Cardioids that mimic human heart development and physiology. Their mission is to accelerate the development of breakthrough therapies for heart failure by building an advanced TechBio platform integrating human biology, AI-driven insights, and automation. The company aims to improve clinical success and patient outcomes by providing precise, customizable, scalable, and cost-effective cardiac models for disease modeling and drug discovery.
Industries
Nr. of Employees
small (1-50)
HeartBeat.bio
Vienna Biocenter 6, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria
Products
Cardiac organoid (cardioid) platform
A platform for generating customizable, self-organizing 3D cardiac organoids that model chamber-like heart structures for disease modeling and drug discovery applications.
Cardiac organoid (cardioid) platform
A platform for generating customizable, self-organizing 3D cardiac organoids that model chamber-like heart structures for disease modeling and drug discovery applications.
Services
Development of tailored 3D cardiac organoid models that replicate disease-specific structural, functional, and molecular features for research and drug discovery applications.
Automated, industry-standard 384-well screening services using organoid models and specialized assays for large-scale compound testing and phenotypic readouts.
Design and execution of assays to quantify structural, functional (including electrophysiological), and molecular endpoints in cardiac organoids for mechanistic studies and compound evaluation.
Integration of laboratory automation and instrumentation to enable high-throughput production and screening of organoid models, including automated workflows and partnerships for scaling.
Application of AI and machine learning for processing screening data, automated quality control, and deriving actionable insights from complex organoid assay outputs.
Development of tailored 3D cardiac organoid models that replicate disease-specific structural, functional, and molecular features for research and drug discovery applications.
Automated, industry-standard 384-well screening services using organoid models and specialized assays for large-scale compound testing and phenotypic readouts.
Design and execution of assays to quantify structural, functional (including electrophysiological), and molecular endpoints in cardiac organoids for mechanistic studies and compound evaluation.
Integration of laboratory automation and instrumentation to enable high-throughput production and screening of organoid models, including automated workflows and partnerships for scaling.
Application of AI and machine learning for processing screening data, automated quality control, and deriving actionable insights from complex organoid assay outputs.
Expertise Areas
- Cardiac organoid development
- iPSC differentiation and cardiomyocyte maturation
- Cardiac disease modeling (fibrosis, cardiomyopathies, cardiotoxicity)
- High-throughput screening and assay automation
Key Technologies
- Induced pluripotent stem cell differentiation
- 3D organoid self-organization
- Organoid fusion / multi-chamber assembly
- ECM-free organoid culture protocols
News & Updates
November 29, 2023: Multi-chamber cardioids mimic human heart development and help understand heart defects.
November 2, 2023: The company secured funding to advance its organoid screening platform.
October 5, 2022: Collaboration to develop new treatments for heart diseases.
September 12, 2022: Partnership to automate and scale cardiac organoids for drug screening.
November 2023: Study on how multi-chamber cardioids mimic human heart development.
August 2021: Review of strategies including self-organizing cardiac organoids.
November 29, 2023: Multi-chamber cardioids mimic human heart development and help understand heart defects.
November 2, 2023: The company secured funding to advance its organoid screening platform.
October 5, 2022: Collaboration to develop new treatments for heart diseases.
September 12, 2022: Partnership to automate and scale cardiac organoids for drug screening.
November 2023: Study on how multi-chamber cardioids mimic human heart development.
August 2021: Review of strategies including self-organizing cardiac organoids.